Welcome to our dedicated page for INSULET SEC filings (Ticker: PODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on INSULET's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into INSULET's regulatory disclosures and financial reporting.
INSULET CORP director Jonathan Jay Mazelsky has filed an initial Form 3 showing no current ownership of the company’s Common Stock. The filing lists him as a director and reports total Common Stock holdings of 0 shares following the reported position. This is an administrative disclosure of his starting ownership status as an insider, and it does not reflect any recent buy or sell transaction in the stock.
INSULET CORP director Robert Luther Huffines received a grant of 144 deferred common stock units, valued at $159.79 per unit. These units were awarded as non-cash compensation under the Company’s Deferred Compensation Plan for Non-Employee Directors and will convert into common shares on a one-for-one basis upon distribution.
After this grant, Huffines is reported as directly holding 2,442 shares of common stock. Distribution of the underlying shares will occur in either a lump sum or substantially equal annual installments, at the director’s election under the plan.
Insulet Corporation appointed Jonathan J. (Jay) Mazelsky as a Class II member of its Board of Directors, effective July 1, 2026. He will stand for election at the Company’s 2027 annual stockholder meeting and will serve as an independent director.
Mazelsky is Executive Chair of IDEXX Laboratories’ board and previously served there as President and CEO, with prior leadership roles at Philips Healthcare, Agilent Technologies, and Hewlett Packard. As a non-employee director, he will receive an initial grant of restricted stock units with a grant date fair value of $216,548, representing a pro-rated $260,000 annual equity award, plus cash compensation under Insulet’s non-employee director compensation program. The Company states there are no related-party arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K.
INSULET CORP director Timothy C. Stonesifer bought shares of the company in the open market. On June 3, he purchased 2,790 shares of Insulet common stock at $143.51 per share. After this transaction, his direct holdings increased to 9,041 common shares.
INSULET CORP director Luciana Borio sold 418 shares of Common Stock in an open-market transaction on June 3, 2026, at an average price of $143.27 per share. After this sale, she directly owns 4,329 company shares, indicating she retains a meaningful ongoing equity stake.
INSULET CORP director Elizabeth H. Weatherman reported an open-market purchase of Common Stock. She bought 3,450 shares at a weighted average price of $144.20 per share, increasing her direct holdings to 10,352 shares after the transaction.
The shares were acquired in multiple trades: 1,607 shares at prices ranging from $143.21 to $144.13 with a weighted average of $143.65, and 1,843 shares at prices ranging from $144.22 to $145 with a weighted average of $144.69.
Insulet Corporation announced a voluntary Medical Device Correction covering specific lots of Omnipod 5, Omnipod DASH, and Omnipod Eros Pods due to a manufacturing issue that can cause insulin under-delivery. The issue stems from cannula tears that may lead to insulin leaking outside the Pod and high blood glucose.
Approximately 7 million Pods are in scope, about 60% of which have already been consumed or expired, and the affected Pods represent roughly 8.5% of 2025 global Omnipod Pod production. Globally, there have been 24 reports of serious adverse events, including hospitalization and diabetic ketoacidosis, but no deaths.
The company has identified the cause, implemented corrective and enhanced quality controls, and is offering free replacement Pods to affected customers. Insulet currently expects up to $50 million of related costs in 2026, to be excluded from adjusted results, and is maintaining its previously issued 2026 guidance and long-term growth outlook.
WEATHERMAN ELIZABETH H reported acquisition or exercise transactions in this Form 4 filing.
Insulet Corp director Elizabeth H. Weatherman received an annual equity award of 1,660 restricted stock units (RSUs). The award is priced at $0.00 per share, indicating it is a stock-based compensation grant rather than a market purchase. These RSUs will settle into common shares on a one-for-one basis and vest in full on April 30, 2027. After this grant, she holds a total of 6,902 shares of Insulet common stock directly.
STONESIFER TIMOTHY C. reported acquisition or exercise transactions in this Form 4 filing.
INSULET CORP director Timothy C. Stonesifer received an annual equity award of 1,660 restricted stock units. The RSUs will settle one-for-one in common stock and vest in full on April 30, 2027. Following this grant, he directly holds 6,251 shares, reflecting routine, compensation-related equity rather than an open-market purchase.